AIIM

AIIM Therapeutics is a South Korean biotechnology company focused on developing innovative RNA-based cancer therapeutics using its proprietary Aptamer-siRNA Chimera (AsiC) technology. The AsiC platform allows for the cell-specific delivery of siRNA by conjugating it with aptamers that recognize specific cell-surface receptors, eliminating the need for complex delivery vehicles like lipid nanoparticles. The company's pipeline primarily targets key oncogenic pathways and immune checkpoints, including STAT3 and CTLA-4, to treat various solid tumors. By leveraging this targeted approach, AIIM Therapeutics aims to enhance the efficacy of gene silencing while minimizing systemic toxicity. The company is currently advancing several programs through pre-clinical development, with a focus on indications such as liver cancer and non-small cell lung cancer. AIIM's technology represents a significant advancement in the field of RNA therapeutics by addressing the long-standing challenge of targeted delivery.